-
公开(公告)号：US20210300973A1
公开(公告)日：2021-09-30
申请号：US17340141
申请日：2021-06-07
IPC分类号： C07K14/335 , A61K38/16 , A61K35/747 , A61K38/13 , C12N1/20 , A61K9/00 , C12N15/74
摘要： The current invention provides a recombinant bacterium, the recombinant bacterium being genetically modified to decrease or eliminate the display of lipoteichoic acid (LTA), surface layer protein B (SlpB) and surface layer protein X (SlpX) on the surface of said bacterium. Efficacious therapies for a subject suffering from an inflammation mediated disease are also provided. The methods of the current invention comprise administering to a subject in need thereof a therapeutically effective amount of the recombinant L. acidophilus cells or a therapeutically effective amount of the isolated surface layer protein A (SlpA) or a non-naturally occurring derivative thereof. The recombinant L. acidophilus cells or SlpA isolated from L. acidophilus can be in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or excipient. In an embodiment of the invention, the pharmaceutical composition is administered orally.
-
2.发明申请LIPOTEICHOIC ACID FROM LACTOBACILLI AS A POTENT IMMUNE STIMULATORY ADJUVANT FOR VACCINE DEVELOPMENT 审中-公开来自Lactobacilli的LIPOTEICHOIC酸作为疫苗开发的免疫刺激性补充剂公开(公告)号：US20170035880A1
公开(公告)日：2017-02-09
申请号：US15303760
申请日：2015-04-23
IPC分类号： A61K39/39 , A61K39/395 , C07K16/28
CPC分类号： A61K39/39 , A61K39/39541 , A61K39/3955 , A61K2039/55511 , A61K2039/55572 , A61K2039/57 , C07K16/2875 , C07K2317/75 , A61K2300/00
摘要： The present invention provides compositions and methods useful for vaccination and generating CD8+ T lymphocyte immune memory against one or more antigens utilizing lipoteichoic acid.
摘要翻译： 本发明提供了可用于接种疫苗并利用脂磷壁酸产生针对一种或多种抗原的CD8 + T淋巴细胞免疫记忆的组合物和方法。
-
3.发明申请公开(公告)号：US20190016762A1
公开(公告)日：2019-01-17
申请号：US15521418
申请日：2015-10-15
IPC分类号： C07K14/335 , C12N15/74 , A61K9/00 , A61K35/747 , A61K38/16
CPC分类号： C07K14/335 , A61K9/0053 , A61K35/747 , A61K38/13 , A61K38/164 , C12N1/20 , C12N15/746 , A61K2300/00
摘要： The current invention provides a recombinant bacterium, the recombinant bacterium being genetically modified to decrease or eliminate the display of lipoteichoic acid (LTA), surface layer protein B (SlpB) and surface layer protein X (SlpX) on the surface of said bacterium. Efficacious therapies for a subject suffering from an inflammation mediated disease are also provided. The methods of the current invention comprise administering to a subject in need thereof a therapeutically effective amount of the recombinant L. acidophilus cells or a therapeutically effective amount of the isolated surface layer protein A (SlpA) or a non-naturally occurring derivative thereof. The recombinant L. acidophilus cells or SlpA isolated from L. acidophilus can be in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or excipient. In an embodiment of the invention, the pharmaceutical composition is administered orally.
-
4.发明申请公开(公告)号：US20200207814A1
公开(公告)日：2020-07-02
申请号：US16804020
申请日：2020-02-28
IPC分类号： C07K14/335 , C12N1/20 , A61K38/13 , C12N15/74 , A61K9/00 , A61K35/747 , A61K38/16
摘要： The current invention provides a recombinant bacterium, the recombinant bacterium being genetically modified to decrease or eliminate the display of lipoteichoic acid (LTA), surface layer protein B (SlpB) and surface layer protein X (SlpX) on the surface of said bacterium. Efficacious therapies for a subject suffering from an inflammation mediated disease are also provided. The methods of the current invention comprise administering to a subject in need thereof a therapeutically effective amount of the recombinant L. acidophilus cells or a therapeutically effective amount of the isolated surface layer protein A (SlpA) or a non-naturally occurring derivative thereof. The recombinant L. acidophilus cells or SlpA isolated from L. acidophilus can be in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or excipient. In an embodiment of the invention, the pharmaceutical composition is administered orally.
-
5.发明申请公开(公告)号：US20200172582A1
公开(公告)日：2020-06-04
申请号：US16790793
申请日：2020-02-14
IPC分类号： C07K14/335 , C12N15/74 , A61K9/00 , A61K35/747 , A61K38/16 , C12N1/20 , A61K38/13
摘要： The current invention provides a recombinant bacterium, the recombinant bacterium being genetically modified to decrease or eliminate the display of lipoteichoic acid (LTA), surface layer protein B (SlpB) and surface layer protein X (SlpX) on the surface of said bacterium. Efficacious therapies for a subject suffering from an inflammation mediated disease are also provided. The methods of the current invention comprise administering to a subject in need thereof a therapeutically effective amount of the recombinant L. acidophilus cells or a therapeutically effective amount of the isolated surface layer protein A (SlpA) or a non-naturally occurring derivative thereof. The recombinant L. acidophilus cells or SlpA isolated from L. acidophilus can be in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or excipient. In an embodiment of the invention, the pharmaceutical composition is administered orally.
-
-
-
-
搜索结果
5 条记录 (耗时 0.016 秒)
